Brief: Palatin Announces Phase IIb Breakout Study Results In Patients With Type 2 Diabetic Nephropathy
19/12/2024 12:54
Dec 19 (Reuters) - Palatin Technologies Inc PTN.A :
* PALATIN ANNOUNCES POSITIVE PHASE IIB BREAKOUT STUDY
RESULTS IN
PATIENTS WITH TYPE 2 DIABETIC NEPHROPATHY
* BREMELANOTIDE WELL TOLERATED WITH NO SERIOUS ADVERSE
EVENTS
Source text: ID:nPn9vl5Zga
Further company coverage: PTN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity